Literature DB >> 32897829

Two Steps Forward and One Step Back for Precision in Prostate Cancer Treatment.

Michael T Schweizer1,2, Heather H Cheng1,2, Peter S Nelson1,2,3, R Bruce Montgomery1,2,4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32897829      PMCID： PMC8265388          DOI： 10.1200/JCO.20.01755

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  8 in total

1.  DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer.

Authors:  Joaquin Mateo; Suzanne Carreira; Shahneen Sandhu; Susana Miranda; Helen Mossop; Raquel Perez-Lopez; Daniel Nava Rodrigues; Dan Robinson; Aurelius Omlin; Nina Tunariu; Gunther Boysen; Nuria Porta; Penny Flohr; Alexa Gillman; Ines Figueiredo; Claire Paulding; George Seed; Suneil Jain; Christy Ralph; Andrew Protheroe; Syed Hussain; Robert Jones; Tony Elliott; Ursula McGovern; Diletta Bianchini; Jane Goodall; Zafeiris Zafeiriou; Chris T Williamson; Roberta Ferraldeschi; Ruth Riisnaes; Bernardette Ebbs; Gemma Fowler; Desamparados Roda; Wei Yuan; Yi-Mi Wu; Xuhong Cao; Rachel Brough; Helen Pemberton; Roger A'Hern; Amanda Swain; Lakshmi P Kunju; Rosalind Eeles; Gerhardt Attard; Christopher J Lord; Alan Ashworth; Mark A Rubin; Karen E Knudsen; Felix Y Feng; Arul M Chinnaiyan; Emma Hall; Johann S de Bono
Journal:  N Engl J Med       Date:  2015-10-29       Impact factor: 91.245

Review 2.  The Tumor Suppressor PALB2: Inside Out.

Authors:  Mandy Ducy; Laura Sesma-Sanz; Laure Guitton-Sert; Anahita Lashgari; Yuandi Gao; Nadine Brahiti; Amélie Rodrigue; Guillaume Margaillan; Marie-Christine Caron; Jacques Côté; Jacques Simard; Jean-Yves Masson
Journal:  Trends Biochem Sci       Date:  2019-01-10       Impact factor: 13.807

3.  Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer.

Authors:  Ronald de Wit; Johann de Bono; Cora N Sternberg; Karim Fizazi; Bertrand Tombal; Christian Wülfing; Gero Kramer; Jean-Christophe Eymard; Aristotelis Bamias; Joan Carles; Roberto Iacovelli; Bohuslav Melichar; Ásgerður Sverrisdóttir; Christine Theodore; Susan Feyerabend; Carole Helissey; Ayse Ozatilgan; Christine Geffriaud-Ricouard; Daniel Castellano
Journal:  N Engl J Med       Date:  2019-09-30       Impact factor: 91.245

4.  Non-BRCA DNA Damage Repair Gene Alterations and Response to the PARP Inhibitor Rucaparib in Metastatic Castration-Resistant Prostate Cancer: Analysis From the Phase II TRITON2 Study.

Authors:  Wassim Abida; David Campbell; Akash Patnaik; Jeremy D Shapiro; Brieuc Sautois; Nicholas J Vogelzang; Eric G Voog; Alan H Bryce; Ray McDermott; Francesco Ricci; Julie Rowe; Jingsong Zhang; Josep Maria Piulats; Karim Fizazi; Axel S Merseburger; Celestia S Higano; Laurence E Krieger; Charles J Ryan; Felix Y Feng; Andrew D Simmons; Andrea Loehr; Darrin Despain; Melanie Dowson; Foad Green; Simon P Watkins; Tony Golsorkhi; Simon Chowdhury
Journal:  Clin Cancer Res       Date:  2020-02-21       Impact factor: 12.531

5.  Evolving Intersection Between Inherited Cancer Genetics and Therapeutic Clinical Trials in Prostate Cancer: A White Paper From the Germline Genetics Working Group of the Prostate Cancer Clinical Trials Consortium.

Authors:  Maria I Carlo; Veda N Giri; Channing J Paller; Wassim Abida; Joshi J Alumkal; Tomasz M Beer; Himisha Beltran; Daniel J George; Elisabeth I Heath; Celestia S Higano; Rana R McKay; Alicia K Morgans; Akash Patnaik; Charles J Ryan; Edward M Schaeffer; Walter M Stadler; Mary-Ellen Taplin; Noah D Kauff; Jacob Vinson; Emmanuel S Antonarakis; Heather H Cheng
Journal:  JCO Precis Oncol       Date:  2018-08-16

6.  Olaparib for Metastatic Castration-Resistant Prostate Cancer.

Authors:  Johann de Bono; Joaquin Mateo; Karim Fizazi; Fred Saad; Neal Shore; Shahneen Sandhu; Kim N Chi; Oliver Sartor; Neeraj Agarwal; David Olmos; Antoine Thiery-Vuillemin; Przemyslaw Twardowski; Niven Mehra; Carsten Goessl; Jinyu Kang; Joseph Burgents; Wenting Wu; Alexander Kohlmann; Carrie A Adelman; Maha Hussain
Journal:  N Engl J Med       Date:  2020-04-28       Impact factor: 91.245

7.  Breast-cancer risk in families with mutations in PALB2.

Authors:  Antonis C Antoniou; William D Foulkes; Marc Tischkowitz
Journal:  N Engl J Med       Date:  2014-10-23       Impact factor: 91.245

8.  Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial.

Authors:  Joaquin Mateo; Nuria Porta; Diletta Bianchini; Ursula McGovern; Tony Elliott; Robert Jones; Isabel Syndikus; Christy Ralph; Suneil Jain; Mohini Varughese; Omi Parikh; Simon Crabb; Angus Robinson; Duncan McLaren; Alison Birtle; Jacob Tanguay; Susana Miranda; Ines Figueiredo; George Seed; Claudia Bertan; Penny Flohr; Berni Ebbs; Pasquale Rescigno; Gemma Fowler; Ana Ferreira; Ruth Riisnaes; Rita Pereira; Andra Curcean; Robert Chandler; Matthew Clarke; Bora Gurel; Mateus Crespo; Daniel Nava Rodrigues; Shahneen Sandhu; Aude Espinasse; Peter Chatfield; Nina Tunariu; Wei Yuan; Emma Hall; Suzanne Carreira; Johann S de Bono
Journal:  Lancet Oncol       Date:  2019-12-02       Impact factor: 41.316
  8 in total
  2 in total

Review 1.  Loose Regulatory Standards Portend a New Era of Imprecision Oncology.

Authors:  Ali Raza Khaki
Journal:  Cancer Invest       Date:  2021-01-07       Impact factor: 2.176

2.  Concordance of DNA Repair Gene Mutations in Paired Primary Prostate Cancer Samples and Metastatic Tissue or Cell-Free DNA.

Authors:  Michael T Schweizer; Smruthy Sivakumar; Hanna Tukachinsky; Ilsa Coleman; Navonil De Sarkar; Evan Y Yu; Eric Q Konnick; Peter S Nelson; Colin C Pritchard; Bruce Montgomery
Journal:  JAMA Oncol       Date:  2021-06-04       Impact factor: 33.006
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.